Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study - Wikidata - awgldk - TriplyDB

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

http://www.wikidata.org/entity/Q35211079

about

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Optimizing treatment success in multiple sclerosis Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.Does Nrf2 help nerves to survive?The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

P2860

Q26752859-35F50F94-53D9-4366-A0A4-E520C4520511 Q26771968-9BA38B4D-54AC-4041-A944-92E4C96399FF Q30965003-B02FE609-7FB0-4341-AA39-C8D4C86E2DF1 Q36202826-46355AFC-0BCB-4595-A7D7-FCF08F41D269 Q36484448-E016FDE4-49AC-4A5A-9F5D-333600F3BA93 Q37459099-4EF1E61B-C59F-4A2F-AB39-ADED4FE62E3C Q38371842-845C4861-D0C8-4D97-8F3C-218297A02707 Q38534132-6DE21197-0BCA-4614-B590-C62183D26A97 Q38675014-BA94447B-862D-4257-B794-516C97293598 Q39298719-47F6AEA1-EBB0-4267-9026-E26AB9E8F3F0 Q40816642-22ED5C2F-3A37-4E1C-8893-9821828C1AD4 Q48168382-5B89AFBA-0491-415C-ACCF-140254B06268 Q49800939-14702622-415C-4043-A50A-B9EF9FD30428 Q52806769-542C3326-241F-4C1E-8E09-4F9B1D14684C Q58756156-26A18EF4-9454-4247-9769-6A66D463538D

P2860

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

http://www.wikidata.org/entity/Q35211079

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@ast

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@en

type

label

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@ast

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@en

prefLabel

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@ast

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@en

P1433

Q35211079-A0E3D823-22D9-4F6C-B8B0-D1150BAFC915

P1476

Q35211079-9FCAA7C8-E6FE-4350-8FDC-0527E82C0A7C

P2093

Q35211079-01B12AD8-4D73-4AFE-8A0E-CFB7DC1B94C8

Q35211079-0403CF10-BDAA-4B27-9E7A-9C7548BB5B26

Q35211079-12E19BA2-82DF-4605-8B58-66DA38A0AD1A

Q35211079-17333014-9D9F-49F9-90D7-B0022740BD84

Q35211079-1DC97695-D23E-4312-8BBC-A76F2FC40889

Q35211079-34AC785A-6077-44C7-BE64-DB242F297045

Q35211079-3914F7B3-688F-4ECA-ACBD-F40631A944A7

Q35211079-57DC98C1-7055-4B10-B3EC-930275A9ADB0

Q35211079-60BA8718-56C0-45E3-B32A-4B97B707160B

Q35211079-672FBFE5-AE6D-4D9C-9756-4C5BE5E76016

P2860

Q35211079-04DDB57D-C3F7-4821-A733-9BC8298FA34C

Q35211079-1862048E-8BD0-4162-82F0-A728222DF171

Q35211079-32AA3AC2-E77C-4F71-8DFF-CA0CD4E8EC6A

Q35211079-49336D5F-69DB-485F-B269-DA9233963815

Q35211079-4A770107-0F06-4B5E-9317-E4C54ADA322B

Q35211079-4E9D86B2-ED97-48B2-B340-AA4D8BF9E40B

Q35211079-645DB74F-2467-4EC1-A4ED-4F57945BB0F2

Q35211079-64A11CAE-BC72-459D-A126-81740D190BB7

Q35211079-6A8F40B3-94DA-4E28-AAB4-FEE042AC6AC4

Q35211079-81595879-D3FA-4562-98B5-75214AF4FA3C

P304

Q35211079-FB59ABCC-F3AD-4EBC-B8B3-BDF312AF98FC

P31

Q35211079-C32C326F-CC82-4330-B704-B673B9CBCBC6

P356

Q35211079-6FE118ED-FF74-43D7-A935-9F17CF3E102E

P407

Q35211079-286CB41E-67BC-48B4-91BE-B820AB8E5F91

P433

Q35211079-7EF5F202-96BB-479D-928D-6194CAC23BE1

P478

Q35211079-28FE5728-BDCE-40CF-B74E-F699C03C0399

P50

Q35211079-434A8C1E-4022-4A21-9C30-52EDD93DEBD3

Q35211079-8E14B45C-0E6B-4682-B209-02972C9A1661

P577

Q35211079-D9C4562B-4B1B-4B1A-8F78-5CE3F026C2CE

P698

Q35211079-ABC9D132-E631-482C-B886-73FF91B00D35

P932

Q35211079-CBAD3138-9A80-48E2-A61D-973099C6A546

P356

WNL.0000000000001360

P1433

P1476

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

@en

P2093

CONFIRM study investigators

http://www.w3.org/2001/XMLSchema#string

Claudia A M Wheeler-Kingshott

http://www.w3.org/2001/XMLSchema#string

Daniel J Tozer

http://www.w3.org/2001/XMLSchema#string

David G MacManus

http://www.w3.org/2001/XMLSchema#string

David H Miller

http://www.w3.org/2001/XMLSchema#string

J Theodore Phillips

http://www.w3.org/2001/XMLSchema#string

Katherine T Dawson

http://www.w3.org/2001/XMLSchema#string

Mariko Kita

http://www.w3.org/2001/XMLSchema#string

Mary Goodsell

http://www.w3.org/2001/XMLSchema#string

Minhua Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Magnetic Resonance Techniques in Multiple Sclerosis

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.

Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.

The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

P304

1145-1152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000001360

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hutchinson

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25681448

http://www.w3.org/2001/XMLSchema#string

P932

4371413

http://www.w3.org/2001/XMLSchema#string